Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.

@article{Torres2018CeftazidimeavibactamVM,
  title={Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.},
  author={Antoni Torres and Nan-shan Zhong and Jan Pachl and Jean-François Timsit and Marin H Kollef and Zhangjing Chen and Jie Song and Dianna Taylor and Peter J Laud and Gregory G. Stone and Joseph Chow},
  journal={The Lancet. Infectious diseases},
  year={2018},
  volume={18 3},
  pages={285-295}
}
BACKGROUND Nosocomial pneumonia is commonly associated with antimicrobial-resistant Gram-negative pathogens. We aimed to assess the efficacy and safety of ceftazidime-avibactam in patients with nosocomial pneumonia, including ventilator-associated pneumonia, compared with meropenem in a multinational, phase 3, double-blind, non-inferiority trial (REPROVE… CONTINUE READING